COMPANY PROFILE / #498
Alloy Therapeutics
Developer of biotechnology platforms intended for drug discovery and development. The company's platform provides engineered biological systems, data-driven systems, antibody discovery capabilities, and integration with machine learning techniques to support target identification, optimization, and preclinical research workflows, enabling pharmaceutical and biotechnology organizations to improve efficiency and reduce uncertainty in therapeutic development processes.Privately Held (backing)
已融资137
最新估值—
员工数—
成立年份Distributed Bio, BioVision, BioLegend, ProSci (Biotechnology), BD Biosciences, eBioscience, Creative Biolabs, Ablexis, Abcam, GenWay BioTech, Regis Technologies, BioAgilytix San Diego, Diagenode, Abveris, Integral Molecular, Allele Biotechnology, PhoreMost, GeneTex, Novus Biologicals, Trianni, Apexigen, X BODY, Eurofins Discovery, Verge Analytics, Novodiax, Genetix Biotherapeutics, Noble Life Sciences, Biological Industries, VLPbio, iBio, Compass Therapeutics, Cell Signaling Technology, Zymo Research, Aviva Systems Biology, Eurofins Calixar, Immunostep, Recombinetics, Harbour Antibodies
公司概况
- Companies
- Alloy Therapeutics
- Description
- —
- Website
- Waltham, MA
- HQ Location
- Developer of biotechnology platforms intended for drug discovery and development. The company's platform provides engineered biological systems, data-driven systems, antibody discovery capabilities, and integration with machine learning techniques to support target identification, optimization, and preclinical research workflows, enabling pharmaceutical and biotechnology organizations to improve efficiency and reduce uncertainty in therapeutic development processes.
- Year Founded
- Distributed Bio, BioVision, BioLegend, ProSci (Biotechnology), BD Biosciences, eBioscience, Creative Biolabs, Ablexis, Abcam, GenWay BioTech, Regis Technologies, BioAgilytix San Diego, Diagenode, Abveris, Integral Molecular, Allele Biotechnology, PhoreMost, GeneTex, Novus Biologicals, Trianni, Apexigen, X BODY, Eurofins Discovery, Verge Analytics, Novodiax, Genetix Biotherapeutics, Noble Life Sciences, Biological Industries, VLPbio, iBio, Compass Therapeutics, Cell Signaling Technology, Zymo Research, Aviva Systems Biology, Eurofins Calixar, Immunostep, Recombinetics, Harbour Antibodies
- Keywords
- 2026: 137, 2025: 134, 2024: 100, 2023: 130, 2022: 102, 2021: 66, 2020: 35, 2019: 17
- Competitors
- —
- Ownership Status
- —
- Company Financing Status
- Privately Held (backing)
融资与估值
- Total Raised
- 137
- First Financing Date
- —
- First Financing Size
- 89
- First Financing Valuation
- errik.anderson@alloytx.com
- Last Financing Date
- 0.09%
- Last Financing Deal Type
- 15-Apr-2026
- Last Financing Size
- Later Stage VC
- Last Financing Valuation
- —
- Last Financing Status
- 1,000.00
- Last Known Valuation
- —
- Last Known Valuation Date
- Later Stage VC
- Last Known Valuation Deal Type
- —
- Valuation Estimate
- 15-Apr-2026
- Valuation Estimate Growth Rate
- accelerated discovery, antibody discovery, antibody discovery platform, antibody drug discovery, biologics and drug development, biologics discovery, drug development platform, human antibodies technology, transgenic mice
- Active Investors
- Venture Capital-Backed
- # Active Investors
- 68%
- Acquirers
- 10X Capital, 8VC, Adam Groff, Alexandria Venture Investments, Calm Ventures, Echo Capital, Founders Fund, Gaingels, Germin8 Ventures, Jesse Robbins, JIC Venture Growth Investments, Jonathan Harshman, Kent Mabalay, LINK-J, Luma Bio-IT Management, Massachusetts Life Sciences Center, Mubadala Capital, New Silk Route Growth Capital, OurCrowd, Peter Thiel, Presight Capital, Thiel Capital, Tony Eng, Ulysses Diversified Holding
团队与联系人
- Employees
- —
- Employee Growth %
- 2017
- Employee History
- —
- Primary Contact
- 173.99
- Primary Contact Title
- +1 (617) 203-7115
- Primary Contact Email
- Errik Anderson
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- 12.26%
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- 281
- Size Multiple
- —
- Size Multiple % Change
- 1,000.00
- Size Multiple Change
- 22.62%
- Size Multiple Percentile
- 3.16x
- Majestic Referring Domains
- 17.13x
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- 433
- Success Probability Over Time – 1 Year
- 84%
- Success Probability Over Time – 3 Year
- 89%
- Success Probability Over Time – 5 Year
- Founder, Chief Executive Officer and Chairman
记录来源：public.companies · 原始序号 #498 · 所有字段均按数据库原值展示。